Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15049437 | 0.80 | CNR2 (0.35) | HTR2CCNR2 | |
| SCHEMBL10609155 | 0.80 | RET (0.35) | HTR2CCNR2SLC6A2RET | |
| SCHEMBL29479374 | 0.80 | RET (0.35) | HTR2CCNR2SLC6A2RET | |
| SCHEMBL4436919 | 0.71 | CYP19A1 (0.38) | HTR2C | |
| SCHEMBL15372611 | 0.69 | RET (0.37) | HTR2CSLC6A2RET | |
| SCHEMBL15049706 | 0.68 | POLB (0.37) | — | |
| SCHEMBL1450862 | 0.67 | MAOA (0.33) | — | |
| SCHEMBL7467393 | 0.67 | HTR2A (0.38) | SLC6A2SLC6A4 | |
| SCHEMBL18959593 | 0.65 | IDO1 (0.44) | SLC6A2SLC6A4 | |
| SCHEMBL16866695 | 0.65 | IDO1 (0.44) | SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230087118-A1 | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2023-03-23 | — | — | US | disclosed |
| EP-3990454-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Biogen MA Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114245796-A | Imidazo [1,2-a ] pyridinyl derivatives and their use in the treatment of disease | 比奥根MA公司 | 2022-03-25 | — | — | CN | disclosed |
| US-11001590-B2 | Pyrazolopyrimidine derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| WO-2020263980-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| US-20200299299-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-09-24 | — | — | US | disclosed |
| US-10604525-B2 | Pyrazolopyrimidine derivatives | BAYAL ANIMAL HEALTH GMBH (DE) | 2020-03-31 | — | — | US | disclosed |
| US-20190071447-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2019-03-07 | — | — | US | disclosed |
| EP-0650476-B1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMA CO LTD (JP) | 2002-06-26 | — | — | EP | disclosed |
| US-6136826-A | AMINOPIPERIDINE COMPOUNDS SUBSTITUTED WITH ALKANOYL | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-24 | — | — | US | disclosed |
| CN-1052224-C | Peripheral Vasodilating agent containing N-acylated 4-amino piperidine derivatives as active ingredients | OTSUKA PHARMA CO LTD (JP) | 2000-05-10 | — | — | CN | disclosed |
| US-5760058-A | Peripheral vasodilating agent containing piperidine derivative as active ingredient | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-02 | — | — | US | disclosed |
| US-5656642-A | Peripheral vasodilating agent containing piperidine derivative as active ingredient | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | disclosed |
| EP-0650476-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-05-03 | — | — | EP | disclosed |
| WO-1994022826-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604525-B2 | Pyrazolopyrimidine derivatives | P2RX5, RECQL, P2RX1 | HTR2C 2958/4885CNR2 1568/4885SLC6A2 4766/4885 |
| US-11001590-B2 | Pyrazolopyrimidine derivatives | P2RX5, RECQL, P2RX1 | HTR2C 2943/4885CNR2 1581/4885SLC6A2 4768/4885 |
| US-20190071447-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | P2RX5, RECQL, P2RX1 | HTR2C 2958/4885CNR2 1568/4885SLC6A2 4766/4885 |
| US-20230087118-A1 | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK2, IRAK1 | HTR2C 3527/4885CNR2 2132/4885SLC6A2 4464/4885 |
| US-20200299299-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES | P2RX5, RECQL, P2RX1 | HTR2C 3122/4885CNR2 1551/4885SLC6A2 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.